Ardelyx (ARDX) to Release Earnings on Thursday

Ardelyx (NASDAQ:ARDX) will be posting its quarterly earnings results after the market closes on Thursday, August 1st. Analysts expect Ardelyx to post earnings of ($0.10) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Ardelyx (NASDAQ:ARDX) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. Ardelyx had a negative return on equity of 41.65% and a negative net margin of 41.36%. The firm had revenue of $46.00 million during the quarter, compared to analyst estimates of $36.40 million. During the same period in the previous year, the company earned ($0.13) EPS. The company’s revenue for the quarter was up 303.5% on a year-over-year basis. On average, analysts expect Ardelyx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ardelyx Stock Performance

Shares of ARDX traded up $0.03 during mid-day trading on Tuesday, hitting $5.59. The company’s stock had a trading volume of 297,338 shares, compared to its average volume of 5,556,821. Ardelyx has a one year low of $3.16 and a one year high of $10.13. The company has a debt-to-equity ratio of 0.66, a quick ratio of 4.36 and a current ratio of 4.53. The firm has a market capitalization of $1.30 billion, a PE ratio of -20.04 and a beta of 0.83. The stock’s 50-day moving average is $6.25 and its two-hundred day moving average is $7.49.

Insider Activity at Ardelyx

In other Ardelyx news, insider Robert Blanks sold 38,000 shares of the stock in a transaction on Friday, June 21st. The stock was sold at an average price of $5.96, for a total transaction of $226,480.00. Following the completion of the transaction, the insider now directly owns 324,331 shares in the company, valued at $1,933,012.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Michael Raab sold 7,500 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $5.97, for a total value of $44,775.00. Following the completion of the sale, the chief executive officer now directly owns 1,260,463 shares in the company, valued at $7,524,964.11. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Robert Blanks sold 38,000 shares of the firm’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $5.96, for a total value of $226,480.00. Following the completion of the sale, the insider now owns 324,331 shares of the company’s stock, valued at $1,933,012.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 504,119 shares of company stock worth $3,917,050. 5.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Ardelyx in a research report on Thursday, July 18th. SVB Leerink assumed coverage on Ardelyx in a research report on Friday, April 5th. They issued an “outperform” rating and a $14.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Ardelyx in a research report on Thursday, June 20th. Piper Sandler cut Ardelyx from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $15.00 to $7.00 in a research report on Tuesday, July 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Ardelyx in a research report on Thursday, July 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Ardelyx currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.69.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.